Medical Health & Life Science Research News

Anxiety disorders drugs market analysis for H2 2016 illuminated by new report

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report: www.rnrmarketresearch.com/anxiety-disorders-pipeline-review-h2-2016-market-report.html

 This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

- Advertising -

- Agency -

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis

Drugs Profile Discussed in this Research:

18-MC,acamprosate calcium SR,ACH-36,ADN-2013,ADX-71441,ADX-71743,ADX-88178, alprazolam,AVN-0189,AM-3506,AVN-101,AVN-628,BNC-210,brexpiprazole,CPP-115,D-473,Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders,E-2508,evenamide, fluvoxamine maleate ganaxolone , GT-001, IC-87201, INT-0036,INV-107,ITI-007,KDAC-0001,ketamine hydrochloride lorazepam,lorazepam ER,modafinil,nabiximols,OMS-527,remeglurant, Rycal       

Companies Discussed/Mentioned in this Research:

AbbVie , Ache Laboratorios Farmaceuticos, Adamed Sp., Amorsa Therapeutics, Addex Therapeutics, Avineuro Pharmaceuticals, Azevan Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Bionomics Limited,Boehringer Ingelheim GmbH,CX Discovery Holdings PLC,Catalyst Pharmaceuticals,Inc.,Corcept Therapeutics Incorporated,Edgemont Pharmaceuticals,LLC,Eisai Co.Ltd.,Eli Lilly and Company,Fabre-Kramer Pharmaceuticals,Inc.,Gabather AB,  GlaxoSmithKline Plc,GW Pharmaceuticals Plc,Humanetics Corporation,IntelGenx Corp.,Intra-Cellular Therapies,Inc.,INVENT Pharmaceuticals,Inc.,Lead Discovery Center GmbH,Marinus Pharmaceuticals,Inc.,Merz Pharma GmbH & Co.KgaA,Neuralstem,Inc.,   Neurelis,Inc.,NeuroNascent,Inc.,Newron Pharmaceuticals S.p.A.,Nippon Chemiphar Co.Ltd.,Omeros

Report: www.rnrmarketresearch.com/contacts/708046

Scope: 

  • The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
  • The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RandD brief, licensing and collaboration details and other developmental activities
  • The report reviews key players involved Anxiety Disorders  therapeutics and enlists all their major and minor projects
  • The report assesses Anxiety Disorders   therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to access

  • Gain strategically significant competitor information, analysis, and insights to formulate effective RandD strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anxiety Disorders   pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Reports Company profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.
...